NOXXON Pharma — ESMO 2019 Conference
21 slides from NOXXON Pharma's conference presentation, Sep 30, 2019
Slide 1: Latest data from Phase 1/2 Study of NOX-A12 and pembrolizumab
Latest data from Phase 1/2 Study of NOX-A12 and pembrolizumab in patients with micro-satellite stable metastatic colorectal or pancreatic cancer ESMO 2019 Conference Poster 30 September 2019
Slide 2: Forward-looking Statements
Forward-looking Statements The information and opinions contained in this presentation and any other information discussed at this presentation are provided as at the date of this presentation and are therefore of a preliminary nature, have not been independently verified and may be subject to updat
Slide 3: Presenters
Presenters Dr. Aram Mangasarian Dr. Jarl Ulf Jungnelius CEO CMO 3
Slide 4: Agenda
Agenda ▪ Key take-aways from the Phase 1/2 NOX-A12 + immunotherapy (Keytruda®/pembrolizumab) – Clinical (Overall Survival) – Mechanism of action ▪ Where does NOX-A12 + immunotherapy fit in the NOXXON pipeline ▪ Standard of care for advanced colorectal and pancreas cancer patients ▪ Trial design, pat
Slide 5: Overall Survival Longer than expected for this Heavily Pre-Treated Population
Overall Survival Longer than expected for this Heavily Pre- Treated Population Responses to immunotherapy Colorectal cancer can take 3-6 patients receiving months to on average their observe and 6th line of therapy many advanced patients don’t Pancreatic cancer have that time patients receiving on a
Slide 6: NOX-A12 Mechanism of Action Highlights – Target
NOX-A12 Mechanism of Action Highlights – Target Neutralization, Immune Response and Stable Disease > 3-fold increase 6 Source: Halama et al, Phase 1/2 Study with CXCL12 Inhibitor NOX-A12 and Pembrolizumab in Patients with Microsatellite-Stable, Metastatic Colorectal or Pancreatic Cancer. ESMO Congre
Slide 7: Pipeline Assets Leverage Existing Anti-Cancer Therapies to Optimize their Therapeutic Efficacy
Pipeline Assets Leverage Existing Anti-Cancer Therapies to Optimize their Therapeutic Efficacy NOX-A12 Indication Combination Preclinical Phase 1 Phase 2 Phase 3 Solid tumors Phase 1/2 trial completed Pancreatic / Colorectal Immunotherapy Patient in follow-up ongoing Update published at Sept 2019 ES
Slide 8: Trial Design
Trial Design 6th line mCRC & 4th line mPaC Dosing • Part A: 2 weeks of NOX-A12 monotherapy: twice per week NOX-A12 • Part B: Combination therapy: NOX-A12 + pembrolizumab given once every 3 weeks Patient population • All patients metastatic with liver metastases and confirmed microsatellite stable tu
Slide 9: Patient Demographics
Patient Demographics 9 Source: Halama et al, Phase 1/2 Study with CXCL12 Inhibitor NOX-A12 and Pembrolizumab in Patients with Microsatellite-Stable, Metastatic Colorectal or Pancreatic Cancer. ESMO Congress 2019 Poster 613P
Slide 10: Standard of Care for Advanced Colorectal and Pancreatic Cancer
Standard of Care for Advanced Colorectal and Pancreatic Cancer Having Failed Prior Lines of Therapy 10 Source: respective US FDA approved product labels
Slide 11: NOX-A12 Monotherapy Triggers Cytokine Signatures Consistent with Th1 Response
NOX-A12 Monotherapy Triggers Cytokine Signatures Consistent with Th1 type Response Making the Tumor ‘Hotter’ ▪ NOX-A12 monotherapy leads to beneficial changes in the tumor microenvironment after 14 days of treatment 15 (PaC) – Increase in concentrations of key cytokines (IL-2 / IFN-γ / IL-16) is Inc
Slide 12: NOX-A12 Mechanism of Action Highlights – Target
NOX-A12 Mechanism of Action Highlights – Target Neutralization, Immune Response and Stable Disease > 3-fold increase 12 Source: Halama et al, Phase 1/2 Study with CXCL12 Inhibitor NOX-A12 and Pembrolizumab in Patients with Microsatellite-Stable, Metastatic Colorectal or Pancreatic Cancer. ESMO Congr
Slide 13: Unexpectedly High Number of Patients with Long Time on Study
Unexpectedly High Number of Patients with Long Time on Study • Overall survival (OS) 42% at 6 months and 22% at • Colorectal cancer patients receiving 6th line of 12 months therapy on average • All patients metastatic with liver metastases and • Pancreatic cancer patients receiving 4th line of confi
Slide 14: Disease Stabilization Following NOX-A12 + Keytruda Therapy
Disease Stabilization Following NOX-A12 + Keytruda® Therapy Seen in Highly Pretreated and Rapidly Progressing Patients Duration Prior Treatment and OPERA Treatment Patients with stable disease only Regardless of the number of prior lines of therapy or outcome of prior therapy, patients can still der
Slide 15: Time on Prior Therapy vs. Time on NOX-A12 + Immunotherapy Study
Time on Prior Therapy (Grey) vs. Time on NOX-A12 + Immunotherapy Study (Blue) • Colorectal cancer patients receiving 6th line of therapy on average • Pancreatic cancer patients receiving 4th line of therapy on average 15 Source: Halama et al, Phase 1/2 Study with CXCL12 Inhibitor NOX-A12 and Pembrol
Slide 16: Progression-free and Overall Survival with NOX-A12 + Pembrolizumab
Progression-free and Overall Survival in Patients Receiving NOX-A12 + Pembrolizumab Combination Therapy • Overall survival (OS) 42% at 6 months and 22% at • Colorectal cancer patients receiving 6th line of 12 months therapy on average • All patients metastatic with liver metastases and • Pancreatic
Slide 17: NOX-A12 Does Not Complicate Pembrolizumab Safety Profile
NOX-A12 Does Not Complicate Pembrolizumab Safety Profile; Ample Room to Optimize NOX-A12 Dosing System Organ Class % Patients with Adverse Events ▪ All adverse events (AEs) are listed which were Preferred Term 0 10 20 30 40 50 reported by at least two patients Abdominal Pain* Constipation Ascites ▪
Slide 18: NOX-A12 Plus Keytruda Shows Induction of Immune Response and Clinical Benefit
NOX-A12 Plus Keytruda® Shows Induction of Immune Response and Clinical Benefit In MSS metastatic PaC and CRC patients with impaired immune systems and a high tumor load that have failed multiple prior lines of therapy, NOX-A12 plus Keytruda® shows induction of immune response and clinical benefit, m
Slide 19: Thinking about future trials – potential combination strategies
Thinking about future trials – what potential combination strategies? NOX-A12 - Enable immune Trafficking of T-cells and cell infiltration & recognition myeloid cells to tumors of cancer cells be effector 4 cells NOX-E36 – clear immunosuppressive myeloid cells from tumor 5 Anti-CTLA4 therapies expan
Slide 20: Questions?
Questions ? 20
Slide 21: Thank you.
Thank you. For more information do not hesitate to contact us at Webcast@noxxon.com 21